Latest news and press releases about Gain Therapeutics, Inc. (GANX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins.
Price
| Price | $1.72 |
| Market Cap | $73M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.46 |
| EV / EBITDA | -3.43 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -161.58% |
| Return on Invested Capital | -157.82% |
| Return on Assets | -130.37% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACET · ADAG · CRVO · FBIO · LITS · NRXP · NTRB
Explore sector: Healthcare · Biotechnology
More sections of GANX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks